Skip to content
value.today

Circle Pharma, Inc.

🇺🇸 San Francisco, California, USAPharmaceuticalsFounded 2012
Total raised
$178 M
4 rounds on record
Latest round
$92 M
Jun 2024
First round on record
Sep 2016
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Circle Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2024$92 MNo. 4$50 to $250 million

Circle Pharma, Inc.: Raise no. 4, Jun 2024

Investors in this round

14 investors had bought by the notice of Jan 10, 2025: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$92 M of $117 M offered; $25 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J. Earp · Executive Officer, Director
  • Paul H. Park · Executive Officer
  • James H. Evangelista · Director
  • John Josey · Director
  • Matthew P. Jacobson · Director
  • Stephen H. Kelsey · Director
  • Thilo H. Schroeder · Director
  • Walter H. Moos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David J. Earp, J.D., Ph.D., President & CEO. Source: SEC Form D and 2 amendments, newest notice filed Jan 10, 2025. Read the notice at the SEC.

equitySEC
Jun 2021$66 MNo. 3$50 to $250 million

Circle Pharma, Inc.: Raise no. 3, Jun 2021

Investors in this round

20 investors had bought by the notice of Mar 22, 2022: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$66 M of $66 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Earp · Executive Officer, Director
  • Elton Satusky · Executive Officer
  • James Evangelista · Director
  • John Josey · Director
  • Matthew Jacobson · Director
  • Thilo Schroeder · Director
  • Walter Moos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David J. Earp, J.D., Ph.D., President & CEO. Source: SEC Form D and 1 amendment, newest notice filed Mar 22, 2022. Read the notice at the SEC.

equitySEC
Mar 2020$15 MNo. 2$10 to $50 million

Circle Pharma, Inc.: Raise no. 2, Mar 2020

Investors in this round

7 investors had bought by the notice of Mar 23, 2020: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $45 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cayla J. McEwen · Executive Officer
  • David J. Earp · Executive Officer, Director
  • Elton J. Satusky · Executive Officer
  • John P. Josey · Director
  • Matthew P. Jacobson · Director
  • Peter P. Svennilson · Director
  • Thilo P. Schroeder · Director
  • Walter P. Moos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David J. Earp, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 23, 2020. Read the notice at the SEC.

equity, optionsSEC
Sep 2016$4 MNo. 1$2 to $10 million

Circle Pharma, Inc.: Raise no. 1, Sep 2016

Investors in this round

4 investors had bought by the notice of Sep 9, 2016: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $6 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J. Earp · Executive Officer, Director
  • Douglas R. Crawford · Director
  • Matthew J. Jacobson · Director
  • Scott R. Lokey · Director
  • Walter R. Moos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David J. Earp, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 9, 2016. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Circle Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).

    SEC Form D · Jan 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2025

That is all the official record says: Circle Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Circle Pharma, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Circle Pharma, Inc.
NameRoleNamed in
David J. EarpExecutive officerJan 2025
Paul H. ParkExecutive officerJan 2025
David EarpExecutive officerMar 2022
Elton SatuskyExecutive officerMar 2022
Cayla J. McEwenExecutive officerMar 2020
Elton J. SatuskyExecutive officerMar 2020
David J. EarpDirectorJan 2025
James H. EvangelistaDirectorJan 2025
John JoseyDirectorJan 2025
Matthew P. JacobsonDirectorJan 2025
Stephen H. KelseyDirectorJan 2025
Thilo H. SchroederDirectorJan 2025
Walter H. MoosDirectorJan 2025
David EarpDirectorMar 2022
James EvangelistaDirectorMar 2022
Matthew JacobsonDirectorMar 2022
Thilo SchroederDirectorMar 2022
Walter MoosDirectorMar 2022
Peter SvennilsonDirectorJun 2021
John P. JoseyDirectorMar 2020
Peter P. SvennilsonDirectorMar 2020
Thilo P. SchroederDirectorMar 2020
Walter P. MoosDirectorMar 2020
Douglas R. CrawfordDirectorSep 2016
Matthew J. JacobsonDirectorSep 2016
Scott R. LokeyDirectorSep 2016
Walter R. MoosDirectorSep 2016